GlassScriptPhysician profile
Scott C Woska
NPI 1326098351
$9,440.41
in general payments reported to CMS, 2019-2025
23 companies · $432 in 2025
The $432 reported for 2025 was more than what 76% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $846 · 2020: $64.41 · 2021: $3,966 · 2022: $626 · 2023: $2,168 · 2024: $1,338 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,187 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $857 · Travel and Lodging: $815 · Entertainment: $78.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,186.88 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $857.00 |
| Travel and Lodging | $815.41 |
| Entertainment | $78.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthofix Medical, INC. | $3,744.00 | 2021 | |
| Relievant Medsystems, INC. | $1,186.54 | 2019-2023 | Intracept |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $857.00 | 2023 | Relistor |
| Nevro Corp. | $640.18 | 2019-2024 | Senza |
| Spr Therapeutics, INC | $553.97 | 2019-2025 | Sprint Pns System |
| Boston Scientific Corporation | $540.42 | 2019-2025 | General - Pain Management, Wavewriter Alpha Prime 16, General - Therapies |
| Medtronic, INC. | $386.55 | 2021-2024 | Intellis Adaptivestim, Vanta Adaptivestim |
| Si-Bone, INC. | $226.58 | 2022-2024 | |
| Vertiflex, INC. | $178.73 | 2019 | |
| Mml US, INC. | $165.27 | 2024 | Reactiv8 |
| Foundation Fusion Solutions, LLC | $163.78 | 2024 | |
| Spinal Elements, INC. | $162.06 | 2024 | |
| Stimwave Technologies Incorporated | $108.79 | 2019 | |
| Abbott Laboratories | $103.50 | 2019-2024 | Eterna |
| Vertex Pharmaceuticals Incorporated | $96.92 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $89.37 | 2023 | Evoke Scs |
| Vertos Medical, INC. | $72.82 | 2021-2024 | Mild Device Kit |
| Spinal Simplicity, LLC | $55.19 | 2025 | Ha Minuteman G3-R |
| Medtronic USA, INC. | $30.73 | 2019 | |
| Nalu Medical, INC. | $25.59 | 2024 | Nalu Neurostimulation System |
| Depuy Synthes Sales INC. | $25.30 | 2019 | |
| Globus Medical, INC. | $15.88 | 2025 | Senza |
| Pacira Pharmaceuticals Incorporated | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$22,494,361.70 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Woska listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.